Comparing thymus, lung, and pancreas neuroendocrine tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial is studying well-differentiated high-grade neuroendocrine tumors that start in the thymus, lung, or pancreas. It compares these tumors to understand them better and find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a well-differentiated high-grade neuroendocrine tumor (Ki-67 over 20%) confirmed by a pathologist.
- The primary tumor must be in the thymus, lung, or duodenum-pancreas.
- Your cancer must be advanced (stage IV or spread) and you can have had any number of prior treatments.
- You must have enough tumor tissue available for testing and complete medical records.
- You cannot have poorly differentiated neuroendocrine carcinoma, mixed tumors, or other primary sites.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
This trial studies a new way to classify and predict outcomes for people with a specific type of neuroendocrine tumor (NET G3). It uses tumor tissue and past scans to better understand your cancer and guide treatment.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
Hear when a new Neuroendocrine Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.